AU740928C - New disubstituted trans-3,4,4a,5,6,10b-hexahydro-2H-naphth (1,2-b)-1,4-oxazines, a process for their preparation and pharmaceutical compositions containing them - Google Patents
New disubstituted trans-3,4,4a,5,6,10b-hexahydro-2H-naphth (1,2-b)-1,4-oxazines, a process for their preparation and pharmaceutical compositions containing themInfo
- Publication number
- AU740928C AU740928C AU83024/98A AU8302498A AU740928C AU 740928 C AU740928 C AU 740928C AU 83024/98 A AU83024/98 A AU 83024/98A AU 8302498 A AU8302498 A AU 8302498A AU 740928 C AU740928 C AU 740928C
- Authority
- AU
- Australia
- Prior art keywords
- oxazines
- hexahydro
- naphth
- preparation
- pharmaceutical compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- AEMKDBZKQORZOA-VXGBXAGGSA-N (4ar,10br)-3,4,4a,5,6,10b-hexahydro-2h-benzo[h][1,4]benzoxazine Chemical class C1=CC=C2[C@H]3OCCN[C@@H]3CCC2=C1 AEMKDBZKQORZOA-VXGBXAGGSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 239000002253 acid Substances 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9710852A FR2767825A1 (fr) | 1997-09-01 | 1997-09-01 | Nouvelles trans-3,4,4a,5,6,10b-hexahydro-2h-napht°1,2-b!-1, 4-oxazines disubstituees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| FR97/10852 | 1997-09-01 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU8302498A AU8302498A (en) | 1999-03-11 |
| AU740928B2 AU740928B2 (en) | 2001-11-15 |
| AU740928C true AU740928C (en) | 2002-05-16 |
Family
ID=9510643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU83024/98A Ceased AU740928C (en) | 1997-09-01 | 1998-09-01 | New disubstituted trans-3,4,4a,5,6,10b-hexahydro-2H-naphth (1,2-b)-1,4-oxazines, a process for their preparation and pharmaceutical compositions containing them |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US6025356A (OSRAM) |
| EP (1) | EP0899267B1 (OSRAM) |
| JP (1) | JP4417451B2 (OSRAM) |
| CN (1) | CN1088064C (OSRAM) |
| AT (1) | ATE229513T1 (OSRAM) |
| AU (1) | AU740928C (OSRAM) |
| BR (1) | BR9803933A (OSRAM) |
| CA (1) | CA2246482C (OSRAM) |
| DE (1) | DE69810034T2 (OSRAM) |
| DK (1) | DK0899267T3 (OSRAM) |
| ES (1) | ES2189108T3 (OSRAM) |
| FR (1) | FR2767825A1 (OSRAM) |
| HU (1) | HU226059B1 (OSRAM) |
| NO (1) | NO311218B1 (OSRAM) |
| NZ (1) | NZ331637A (OSRAM) |
| PL (1) | PL194533B1 (OSRAM) |
| PT (1) | PT899267E (OSRAM) |
| ZA (1) | ZA987963B (OSRAM) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0130219D0 (en) * | 2001-12-18 | 2002-02-06 | Pfizer Ltd | Compounds for the treatment of sexual dysfunction |
| MXPA05002331A (es) * | 2002-08-30 | 2005-08-18 | Biostratum Inc | Inhibidores de productos terminales de glicacion avanzada post-amadori. |
| MXPA05011225A (es) * | 2003-04-18 | 2005-12-14 | Pharmacia & Upjohn Co Llc | Politerapias. |
| FR2906249B1 (fr) * | 2006-09-26 | 2008-12-19 | Servier Lab | Composes tetracycliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| EP2098511A1 (en) | 2008-03-07 | 2009-09-09 | Solvias AG | Process for preparing compounds containing a hydronaphtalene structure with an unsymmetrically substituted benzene ring |
| EP2303851A1 (en) * | 2008-06-27 | 2011-04-06 | H. Lundbeck A/S | Novel phenolic and catecholic amines and prodrugs thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0080115A2 (en) * | 1981-11-20 | 1983-06-01 | Merck & Co. Inc. | Hexahydronaphth(1,2-b)-1,4-oxazines, process for their preparation and pharmaceutical formulation containing them |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4420480A (en) * | 1981-11-20 | 1983-12-13 | Merck & Co., Inc. | Hexahydronaphth[1,2-b]-1,4-oxazines |
| US4540691A (en) * | 1984-04-13 | 1985-09-10 | Nelson Research & Development Co. | Dopamine agonists and use thereof |
| US5486611A (en) * | 1989-07-13 | 1996-01-23 | The Upjohn Company | Carboxamido-(1,2N)-carbocyclic-2-aminotetralin derivatives |
| WO1991019719A1 (en) * | 1990-06-15 | 1991-12-26 | Whitby Research, Inc. | Substituted naphthoxazines useful as dopaminergics |
-
1997
- 1997-09-01 FR FR9710852A patent/FR2767825A1/fr active Pending
-
1998
- 1998-08-31 NO NO19984007A patent/NO311218B1/no not_active IP Right Cessation
- 1998-08-31 PL PL328285A patent/PL194533B1/pl not_active IP Right Cessation
- 1998-08-31 US US09/144,025 patent/US6025356A/en not_active Expired - Lifetime
- 1998-08-31 BR BR9803933-4A patent/BR9803933A/pt not_active Application Discontinuation
- 1998-08-31 NZ NZ331637A patent/NZ331637A/xx not_active IP Right Cessation
- 1998-08-31 CA CA002246482A patent/CA2246482C/fr not_active Expired - Fee Related
- 1998-08-31 HU HU9801951A patent/HU226059B1/hu not_active IP Right Cessation
- 1998-08-31 CN CN98119987A patent/CN1088064C/zh not_active Expired - Fee Related
- 1998-09-01 DE DE69810034T patent/DE69810034T2/de not_active Expired - Lifetime
- 1998-09-01 DK DK98402155T patent/DK0899267T3/da active
- 1998-09-01 ES ES98402155T patent/ES2189108T3/es not_active Expired - Lifetime
- 1998-09-01 EP EP98402155A patent/EP0899267B1/fr not_active Expired - Lifetime
- 1998-09-01 ZA ZA987963A patent/ZA987963B/xx unknown
- 1998-09-01 AU AU83024/98A patent/AU740928C/en not_active Ceased
- 1998-09-01 PT PT98402155T patent/PT899267E/pt unknown
- 1998-09-01 JP JP24691098A patent/JP4417451B2/ja not_active Expired - Fee Related
- 1998-09-01 AT AT98402155T patent/ATE229513T1/de active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0080115A2 (en) * | 1981-11-20 | 1983-06-01 | Merck & Co. Inc. | Hexahydronaphth(1,2-b)-1,4-oxazines, process for their preparation and pharmaceutical formulation containing them |
Also Published As
| Publication number | Publication date |
|---|---|
| ZA987963B (en) | 1999-03-04 |
| HU226059B1 (en) | 2008-04-28 |
| PL194533B1 (pl) | 2007-06-29 |
| DK0899267T3 (da) | 2003-03-10 |
| EP0899267B1 (fr) | 2002-12-11 |
| EP0899267A1 (fr) | 1999-03-03 |
| DE69810034D1 (de) | 2003-01-23 |
| JPH11130759A (ja) | 1999-05-18 |
| ATE229513T1 (de) | 2002-12-15 |
| JP4417451B2 (ja) | 2010-02-17 |
| DE69810034T2 (de) | 2003-08-14 |
| HUP9801951A2 (hu) | 2000-02-28 |
| AU8302498A (en) | 1999-03-11 |
| HU9801951D0 (en) | 1998-11-30 |
| CN1222516A (zh) | 1999-07-14 |
| US6025356A (en) | 2000-02-15 |
| NO984007D0 (no) | 1998-08-31 |
| NZ331637A (en) | 1999-07-29 |
| BR9803933A (pt) | 2001-04-24 |
| AU740928B2 (en) | 2001-11-15 |
| ES2189108T3 (es) | 2003-07-01 |
| HUP9801951A3 (en) | 2000-04-28 |
| CA2246482C (fr) | 2002-11-26 |
| CN1088064C (zh) | 2002-07-24 |
| PT899267E (pt) | 2003-04-30 |
| NO311218B1 (no) | 2001-10-29 |
| HK1020340A1 (en) | 2000-04-14 |
| CA2246482A1 (fr) | 1999-03-01 |
| NO984007L (no) | 1999-03-02 |
| FR2767825A1 (fr) | 1999-02-26 |
| PL328285A1 (en) | 1999-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2464997A (en) | New 3-(piperid-4-YL)-1,2-benzisoxazole and 3-piperazin-4-YL)-1,2-benzisoxazole compounds, processes for their preparation and pharmaceutical compositions containing them | |
| AU645867B2 (en) | 2-arylthiazole derivative and pharmaceutical composition containing the same | |
| HU9600278D0 (en) | Remedy for nervous diseases | |
| HUP0000610A2 (hu) | Fájdalomcsillapító hatású piperidinszármazékok, eljárás előállításukra és a vegyületeket tartalmazó gyógyszerkészítmények | |
| DE68908040D1 (de) | 3-(4-piperidin)-5-(2-sulphonylaminoethyl)-indol-derivate. | |
| PL359415A1 (en) | Oxadiazole derivatives having anticancer effects | |
| AU740928C (en) | New disubstituted trans-3,4,4a,5,6,10b-hexahydro-2H-naphth (1,2-b)-1,4-oxazines, a process for their preparation and pharmaceutical compositions containing them | |
| ZA964842B (en) | Indole indazole and benzisoxazole compounds their process of preparation and the pharmaceutical compositions which contain them | |
| HU0000308D0 (en) | New cyano-indole serotonin-reuptake inhibitor compounds, a process for their preparation and pharmaceutical compositions containing them | |
| AU7170496A (en) | New tetracyclic 1,4-oxazine compounds, a process for their preparation and pharmaceutical compositions containing them | |
| IL116386A (en) | Preparation of pharmaceutical compositions containing 1,2-bridged 1,4-dihydropyridines for the control of cns disorders and sickle cell anemia certain such novel compounds and their preparation | |
| AU621239B2 (en) | Novel 2-oxo-1-oxa-8-azaspiro(4,5)decane derivatives, pharmaceutical compositions containing them and process for preparing the same | |
| AU4012393A (en) | New diacylglycerol nicotinates, process for their preparation and pharmaceutical compositions which contain them | |
| AU1494295A (en) | Novel aminoalkyl benzothiazolinones, process for their preparation and the pharmaceutical compositions which contain them | |
| HU903875D0 (en) | Process for producing new thioformamide derivatives and pharmaceutical preparatives containing these compounds | |
| AT389309B (de) | Malonsaeurederivate, verfahren zu ihrer herstellung und pharmazeutische zusammensetzung, enthaltend diese verbindungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE PROPOSED AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 20011005 |
|
| PC1 | Assignment before grant (sect. 113) |
Owner name: LES LABORATOIRES SERVIER Free format text: THE FORMER OWNER WAS: ADIR ET COMPAGNIE |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ MARK MILLAN |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS WAS NOTIFIED IN THE OFFICIAL JOURNAL DATED 20011115 |